LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

LLY

992.22

-1.17%↓

JNJ

228.35

+0.7%↑

ABBV

209.02

-0.67%↓

UNH

387.28

-1.62%↓

AZN

184.54

+1.61%↑

Inicio・Lista de Acciones・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Abierto

SectorSanidad

8.96 -0.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.76

Máximo

9.01

Métricas clave
By Trading Economics
Ingresos	-1.1B -722M
Ventas	-250M 156M
P/B Media del Sector	7.603 51.415
BPA	0.141
Margen de beneficios	-461.478
Empleados	435
EBITDA	-968M -702M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+158.65% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-157M 2.2B
Apertura anterior	9.51
Cierre anterior	8.96

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

69 / 345 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 may 2026, 23:53 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 may 2026, 22:47 UTC

Acciones populares

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 may 2026, 22:16 UTC

Adquisiciones, fusiones, absorciones

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 may 2026, 22:00 UTC

Principales Movimientos del Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 may 2026, 18:09 UTC

Principales Movimientos del Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 may 2026, 23:50 UTC

Charlas de Mercado

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

17 may 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 may 2026, 23:36 UTC

Charlas de Mercado

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 may 2026, 23:07 UTC

Adquisiciones, fusiones, absorciones

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 may 2026, 23:06 UTC

Adquisiciones, fusiones, absorciones

UOB: Share Sale Agreements Entered With Singland Properties

17 may 2026, 23:05 UTC

Adquisiciones, fusiones, absorciones

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire Stake for $389 Million

17 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 may 2026, 16:27 UTC

Adquisiciones, fusiones, absorciones

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 may 2026, 15:26 UTC

Adquisiciones, fusiones, absorciones

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 may 2026, 08:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 22:17 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 may 2026, 21:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 may 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 may 2026, 21:16 UTC

Charlas de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 may 2026, 20:19 UTC

Acciones populares

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 may 2026, 19:41 UTC

Adquisiciones, fusiones, absorciones

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 may 2026, 19:35 UTC

Charlas de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 may 2026, 19:33 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 may 2026, 18:35 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

158.65% repunte

Estimación a 12 Meses

Media 23.33 USD 158.65%

Máximo 32 USD

Mínimo 13 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

69 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.